Introduction
Kit, the receptor for stem cell factor (SCF), is a Type III receptor tyrosine kinase of the platelet-derived growth factor (PDGF) subfamily. c-kit maps to the white spotting (W) locus in the mouse 1,2 while the gene for its ligand SCF maps to the steel (Sl) locus. 3, 4 Mutations that reduce function or expression of either the receptor or ligand lead to macrocytic anemia, mast cell deficiency, abnormal pigmentation of skin and hair, infertility, reduced gastrointestinal motility, and impaired hippocampal learning. 5 Gain of function mutations in Kit can be oncogenic and are found in various diseases including leukemias, mastocytosis, germ cell tumors, and gastrointestinal stromal tumors (GISTs). 6 One common gain of function mutation is the substitution of valine, tyrosine, asparagine, or histidine for aspartic acid 816 in the catalytic domain of human Kit. Mutations of codon 816 have been identified in patients with mastocytosis, 7-10 acute myeloid leukemia, [11] [12] [13] and germ cell tumors. 14 Mutations of the corresponding codon (D814 in mice, D817 in rats) have been found in a murine mastocytoma cell line P-815 15 and a rat mast cell tumor line RBL-2H3. 16 Expression of D814Y/V Kit in the murine mast celllike line IC2, as well as several other factor-dependent hematopoietic cell lines, results in factor-independent growth and tumorigenesis. [17] [18] [19] [20] Interestingly, cells expressing a Kit catalytic domain mutant are resistant to Gleevec/STI571/Imatinib, an inhibitor of wildtype Kit. [21] [22] [23] Thus, drugs targeting this mutant receptor or its downstream effectors could be useful therapeutic agents in the treatment of diseases associated with this mutation.
The protein kinase C (PKC) family of serine-threonine protein kinases encompasses at least twelve members, 24 which can be separated into three classes:
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From conventional, novel, and atypical. The conventional PKCs include the , , and isoforms. Activation of these PKCs requires both calcium ions and a lipid, such as diacylglycerol (DAG) or phosphatidylserine, or a phorbol ester. The novel PKCs, including , , , and isoforms, are calcium-independent and require only a lipid or a phorbol ester for kinase activity. Unlike the conventional isoforms, the novel isoforms can be activated by the products of PI3K, PtdIns-3,4-P 2 or PtdIns-3,4,5-P 3, as well as DAG or phosphatidylserine. 25 The atypical PKCs, including the and isoforms, require neither calcium nor a lipid or phorbol ester for kinase activity.
PKC isoforms are reported to phosphorylate wild-type Kit on serine residues after stimulation with SCF. Previous work has shown this reduces autophosphorylation activity and subsequent interaction with a variety of signaling components. 26, 27 Importantly, these studies were performed in porcine aortic endothelial cells, which predominantly express the conventional PKC isoforms and . The role of novel PKC isoforms in signaling through wild-type Kit has not been addressed. Further, little is known about the role of PKC isoforms in transformation mediated by oncogenic Kit mutants. Interestingly, recent work has implicated PKC in B cell lymphocytic leukemia 28 and multiple myeloma. 29 The objective of this study was to investigate the role of PKC in responses mediated by a normal and an oncogenic form of Kit. We found that while PKC is activated after SCF stimulation of wild-type Kit and is constitutively active in cells expressing the D814Y mutant, it plays a different role in growth mediated by these two forms of Kit. were prepared using a high phosphatase inhibitor (HPI) lysis buffer (1% Triton-X-100, 10 mM Tris-HCl, 50 mM NaCl, 5 mM EDTA, 30 mM tetrasodium pyrophosphate, 25 mM -glycerophosphate, 5 mM sodium orthovanadate, 1 mg/ml p-nitrophenyl phosphate, and 5 mM sodium fluoride, pH 7.5). Lysates were incubated on ice for 20 min and then centrifuged at 14,000 rpm for 30 min at 4°C. Clarified lysates were stored at -70°C.
Membrane-enriched fractions were prepared as follows: Cells were resuspended in hypotonic 5/5/5 buffer (5mM Tris, 5mM EDTA, 5mM EGTA, pH 7.5) and kept on ice for 15 min before being drawn four times through a 22 gauge needle then four times through a 27 gauge needle. Membranes were pelleted at 35,000 rpm for 15 min at 4°C in a SW50.1 rotor in a Beckman ultracentrifuge (Palo Alto, CA). Pellets were resuspended in HPI buffer and rotated for 2 hrs at 4°C to solubilize. Triton-X-100 insoluble material was pelleted and discarded. Membrane-enriched fractions were stored at -70°C. The protein concentrations of the clarified lysates and membrane preparations were determined using the BCA assay (Pierce, Rockford, IL) with bovine serum albumin as a standard.
Depending upon the experiment, between 300 and 800 µg of protein and 1 µg of antibody was used per immunoprecipitation. Immunoprecipiates were resolved by SDS-PAGE and then transferred to Immobilon-P membranes (Millipore, Billerica, MA).
Immunoblots were blocked in TBST with 0.1% BSA, 2% goat serum, and 1% liquid IC2 cells expressing D814Y Kit were factor-independent and tumorigenic in mice. 19, 20 To investigate the role of PKC in responses mediated by a normal and an oncogenic form of Kit, we first examined PKC activity in IC2 cells expressing wild-type or D814Y Kit. In vitro immune complex kinase assays were performed on PKC immunoprecipitated from equivalent amounts of protein from whole cell lysates of cells expressing wild-type or D814Y Kit. As shown in Figure 1A , (Fig. 3A) . Ponceau S staining indicated that equivalent amounts of substrate were present (data not shown).
Further, the higher levels of PKC activity were not mediated by increases in the amount of PKC protein in the membrane fractions of cells expressing D814Y Kit (Fig. 3B ). In fact, less PKC was observed in the samples from cells expressing D814Y Kit than cells expressing wild-type Kit (Fig. 3B ). This contrasts with the data shown in Figure 2B Figure 4B demonstrates that similar amounts of Kit were present in each immunoprecipitate.
Consistent with the above findings, there was also serine kinase activity associated with Kit immunoprecipitates from cells expressing wild-type or mutant Kit.
Of note was an increase in activity associated with D814Y Kit compared to wild-type Kit (data not shown). This is consistent with the coprecipitation of PKC with both wildtype and mutant Kit (Fig. 4) , as well as with the increase in total PKC activity ( Fig. 1) and membrane associated PKC activity (Fig. 3 ) in cells expressing mutant Kit.
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However, it is possible that this activity could represent an additional serine kinase in the Kit receptor complex.
Although PKC was readily detected in Kit immunoprecipitates, Kit protein was not observed in the PKC control immunoprecipitate (Fig 4B) . Several Kit antibodies were used in these studies, however many of the commercially available antibodies recognize human Kit and are less effective at detecting murine Kit. Thus, the low sensitivity of the Kit specific antibody in immunoblotting murine Kit probably accounts for this result. 35 the effect on the growth of both types of cells was essentially the same (Fig.   5C ). In addition, as in the rottlerin experiment, the addition of SCF did not alter the response of cells expressing D814Y Kit to Gö6976 (Fig. 5D ). These data suggest that PKC contributes to factor-independent growth mediated by the Kit catalytic domain mutant, but may be involved in negative regulation of wild-type Kit. These data are of particular note since the effective dose of rottlerin (500 nM) is an order of magnitude lower than the 5 µM amount reported to have nonspecific effects. (Fig. 6A) . These results are consistent with PKC acting as a negative regulator of SCF-activated Kit in these cells. In contrast, expression of the wild-type PKC construct in cells expressing D814Y Kit enhanced factor-independent growth by 90% percent, while expression of the dominant negative construct reduced factor-independent growth by nearly 50% (Fig. 6B ).
In addition, SCF did not alter the effect of the PKC constructs on responses of cells expressing D814Y Kit (Fig. 6C ). These data, in conjunction with the results with the PKC inhibitor rottlerin, indicate that PKC is a negative regulator of SCF-stimulated Consistent with previous studies, tyrosine 705 of the STAT3 and isoforms was constitutively phosphorylated in cells expressing D814Y Kit (Fig. 7A) . 20, 38, 39 In addition, Figure 7A shows that serine 727 of STAT3 is also constitutively phosphorylated in cells expressing D814Y Kit. The STAT3 and isoforms do not contain serine 727. Some increase in serine phosphorylation of STAT3 was also noted after SCF stimulation of cells expressing wild-type Kit. Reprobing the membranes with an antibody specific for STAT3 demonstrated that STAT3 is expressed at equal levels by cells expressing wildtype and D814Y Kit (Fig. 7B ).
Since both PKC and JNKs are activated in cells expressing the Kit catalytic domain mutant, these data raise the intriguing possibility that STAT3 is activated 
Discussion
In this study we examined the role of PKC in responses mediated by wild-type and D814Y murine Kit in a murine mast cell-like line. PKC was activated after SCF stimulation of cells expressing wild-type Kit and was constitutively active in cells expressing mutant Kit (Figures 1 and 3) . Further, PKC activity was consistently higher in cells expressing D814Y Kit than cells expressing wild-type Kit (Figures 1 and 3 ). This increase in kinase activity correlated with increases in tyrosine phosphorylation of PKC associated with membrane fractions (Figure 2) . A positive link between tyrosine phosphorylation and PKC activity has been observed in some studies. 32, 33 This report is the first demonstration that either wild-type Kit or the Kit catalytic domain mutant activates PKC .
Although PKC is activated in cells expressing either wild-type or mutant Kit, we found that this serine kinase promotes growth of cells expressing D814Y Kit but inhibits growth of cells expressing wild-type Kit. This was illustrated in studies inhibiting PKC either with rottlerin or through ectopic expression of dominant negative PKC constructs (Figures 5 and 6 ). Further, overexpression of wild-type PKC had opposite effects on cells expressing wild-type and mutant Kit (Figure 6 ). In addition, SCF does not alter the One mechanism that could mediate the different outcome of PKC activation in cells expressing wild-type and mutant Kit could be changes in substrate specificity that lead to enhanced activation of one or more signaling pathways. Indeed, previous studies have suggested that phosphorylation on tyrosine alters PKC substrate recognition.
32,48
Here we show increases in PKC activity and tyrosine phosphorylation in membrane fractions of cells expressing the Kit catalytic domain mutant. We also observed an increase in phosphorylation of STAT3 on serine 727, a residue known to be a target for PKC 49, 50 ( Figures 2, 3 and 7) . However, a variety of MAP kinase family members can also phosphorylate serine 727 of STAT3. [51] [52] [53] [54] In cells expressing the Kit catalytic domain The introduction of inhibitors specific to other PKC isoforms, particularly PKC , may advance treatment of hematologic disease since PKC has been associated with several hematologic malignancies. Indeed, the present work suggests that PKC may be a therapeutic target in mastocytosis or AML associated with mutations in the catalytic domain of Kit. Other recent work has linked PKC expression to B cell chronic lymphocytic leukemia, 28 multiple myeloma, 29 and inappropriate survival of neutrophils, 47 which occurs in inflammatory diseases. PKC inhibitors offer the possibility of a novel therapy with potentially less toxicity than traditional chemotherapy since PKC412 and 
